Skip to main content
GILD
NASDAQ Life Sciences

Livdelzi Hits 75.4% ALP Normalization at Week 52 in Phase 3 PBC Study

Tom Rudovsky · Reported by Reuters
More coverage: Pharmaceutical Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$174.565
Mkt Cap
$216.52B
52W Low
$116.88
52W High
$176.58
52W Position info
49% above low
Off High info
1.1% below high
Rel. Volume info
0.3× avg
Market data snapshot near publication time

GILD sits 49% above its 52-week low of $116.88 on light trading volume (0.3× avg).

Summary

Gilead's Phase 3 IDEAL study showed 75.4% of Livdelzi (seladelpar) patients reached ALP normalization at week 52 versus 16.1% on placebo — a roughly four-and-a-half-fold gap in the second-line PBC population. Safety cut the other way too: serious adverse events were 3.1% on Livdelzi versus 12.9% on placebo, with none drug-related. The data strengthen the label story for a drug already approved, giving Gilead hard long-term normalization numbers to take to payers and prescribers rather than just biochemical response rates. It lands two weeks after the Q3 beat and raised 2026 product sales guidance of $31.0-31.3 billion, and follows the October 19 emvistegrast ulcerative colitis win — a run of clinical positives that supports the base business. Modest near-term revenue impact since Livdelzi is already on the market; the value is in share gains within PBC and payer leverage.

At the time of this announcement, GILD was trading at $174.57 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $216.5B. The 52-week trading range was $116.88 to $176.58. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Reuters.


Price Chart

Share this article

Copied!

GILD - Latest Insights

GILD
Oct 29, 2026, 4:03 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $165.88
Real-time Price: $173.67 info
Change: +$7.79 (+5%) info
Market Cap: $215.41B info
GILD
Oct 29, 2026, 4:02 PM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $164.00
Real-time Price: $173.67 info
Change: +$9.67 (+6%) info
Market Cap: $215.41B info
GILD
Oct 22, 2026, 4:05 PM EDT
Source: BusinessWire
Importance Score:
7
Price at Filing: $157.19
Real-time Price: $173.67 info
Change: +$16.48 (+10%) info
Market Cap: $215.41B info
GILD
Oct 19, 2026, 6:40 AM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $156.82
Real-time Price: $173.67 info
Change: +$16.85 (+11%) info
Market Cap: $215.41B info
GILD
Sep 21, 2026, 5:20 AM EDT
Source: Moneycontrol
Importance Score:
7
Price at Filing: $149.00
Real-time Price: $173.67 info
Change: +$24.67 (+17%) info
Market Cap: $215.41B info